Latest Fund Strategy News

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

Wisr Limited reports robust half-year growth with a 23% increase in its loan book and a 14% rise in revenue, setting the stage for expected cash profitability in the second half of FY26.

Elixir Energy has locked in a $10 million debt facility secured against its FY26 R&D tax refund to fund the Lorelle-3 appraisal well activities in Queensland’s Taroom Trough. This financial move aims to bolster working capital during a busy operational period.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Talga Group’s application for a major Swedish government grant was declined due to budget constraints, yet the company remains on track with alternative financing to scale its graphite anode production.

Caravel Minerals has secured non-binding Letters of Interest from Finnish and German export credit agencies, marking a significant step in financing its Caravel Copper Project. This European backing complements a diversified funding strategy as the company moves towards a Final Investment Decision.

Austral Resources Australia has voluntarily suspended its shares on the ASX to complete a significant placement and secure a strategic investor commitment, with strong demand reported.

Empire Resources has successfully raised nearly $2.9 million through the first tranche of its planned $5 million placement, with a second tranche pending shareholder approval in March.

Stavely Minerals has locked in a $500,000 unsecured director loan facility to fund its 2026 Scoping Study targeting copper, gold, and silver production. This non-dilutive funding move underscores confidence from within the board as the company advances key projects.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Kali Metals Limited has successfully raised approximately A$7 million through a Tranche 1 Placement, issuing over 38 million new shares at 18 cents each. This capital injection marks a significant step in the company’s funding strategy.

Malcolm Mines NL’s subsidiary has taken key steps towards establishing a 500,000 tonnes per annum gold processing facility at Leonora, signing critical agreements for technical and funding expertise.